- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
- Novocure to Report First Quarter 2024 Financial Results
- Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
More ▼
Key statistics
On Tuesday, Novocure Ltd (NVCR:NSQ) closed at 22.32, 105.34% above the 52 week low of 10.87 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.56 |
---|---|
High | 23.67 |
Low | 21.64 |
Bid | 21.50 |
Offer | 23.74 |
Previous close | 22.32 |
Average volume | 1.73m |
---|---|
Shares outstanding | 107.61m |
Free float | 97.65m |
P/E (TTM) | -- |
Market cap | 2.40bn USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼